Antibody-Drug Conjugates

Daiichi-Merck partnership lines up Keytruda combo therapy

09-Oct-2018 By Maggie Lynch

Daiichi Sankyo announced it has entered into a clinical trial collaboration agreement with Merck & Co. to evaluate an investigational lung cancer treatment.

Regeneron and Sanofi receives first US FDA approval for PD-1 treatment

03-Oct-2018 By Maggie Lynch

The US FDA approved the first drug created by the 2015 partnership between Regeneron and Sanofi to research and develop immuno-oncology therapies.

Partnership to provide oncology portfolio with a translational platform

19-Sep-2018 By Maggie Lynch

Mitra Biotech and Glenmark Pharmaceuticals have partnered to advance research on Glenmark’s immuno-oncology treatments using Mitra’s platform.

US FDA approves expanded label for Merck’s Keytruda as first-line treatment for NSCLC

22-Aug-2018 By Maggie Lynch

The US FDA has approved an expanded label for Merck’s Keytruda in combination with pemetrexed and platinum chemotherapy.

Daiichi Sankyo and Glycotope reach agreement for “first-in-class” ADC

03-Aug-2018 By Maggie Lynch

Daiichi Sankyo and Glycotope have signed a licensing agreement to develop an antibody-drug conjugate that enables tumor-specific binding to TA-MUC1.

ADC Bio: Biotech may 'hold the key' to innovation adoption

08-Jun-2018 By Flora Southey

CDMOs need to respond to biotech innovation at an R&D level to improve efficiency in antibody-drug conjugate manufacturing, says ADC Bio.

The Golden Ticket: Sanofi, Meditope initiate research collaboration to explore bioconjugation tech

09-May-2018 By Melissa Fassbender

Sanofi has awarded Meditope Biosciences a BioLabs’ “Golden Ticket” to support the development of its bioconjugation platform and create new antibody-based therapeutic constructs.